Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Government policy is hurting creativity say Nobel Laureates

This article was originally published in Scrip

Executive Summary

A clutch of Nobel Laureates believe that directing government research funding to projects that are expected to produce economic benefits is misguided. The UK's switch in the 1970s to more targeted research funding, for example, correlated with a decline 20 years later in the number of prizes that the country won. The big advances in science, and resultant economic benefit, come from discoveries that cannot be predicted, claim Sir Tim Hunt, Sir Aaron Klug and others, in a letter to the Financial Times (June 24th, p 14).

You may also be interested in...



Pipeline Watch: The Bumper ASCO Edition

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

European Biotech: Innovation Hotspots To Drive Growth

Europe’s strengths in the biotech space include world-class science, but the continent needs to build on its strengths in order to deliver on the promise of a coming “golden age” of biotech, says a recent report.

Byondis Seeks Partner For Lead ADC To Enter Crowded Breast Cancer Market

Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.

UsernamePublicRestriction

Register

SC002945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel